VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy [version 1; referees: 2 approved]

For several complex intracellular pathogens, we have an urgent need for effective vaccines and yet there are common barriers to vaccine development. These diseases, including tuberculosis, leishmaniasis, leprosy and melioidosis, cause a huge burden of disease and disproportionately affect low and mi...

Full description

Bibliographic Details
Main Authors: Helen A. Fletcher, Mitali Chatterjee, Andrea Cooper, Tracy Hussell, Paul M. Kaye, Joann Prior, Rajko Reljic, Samantha Vermaak, Martin Vordermeier, Ann Williams, Helen McShane
Format: Article
Language:English
Published: F1000 Research Ltd 2018-04-01
Series:F1000Research
Online Access:https://f1000research.com/articles/7-485/v1
_version_ 1818994442673061888
author Helen A. Fletcher
Mitali Chatterjee
Andrea Cooper
Tracy Hussell
Paul M. Kaye
Joann Prior
Rajko Reljic
Samantha Vermaak
Martin Vordermeier
Ann Williams
Helen McShane
author_facet Helen A. Fletcher
Mitali Chatterjee
Andrea Cooper
Tracy Hussell
Paul M. Kaye
Joann Prior
Rajko Reljic
Samantha Vermaak
Martin Vordermeier
Ann Williams
Helen McShane
author_sort Helen A. Fletcher
collection DOAJ
description For several complex intracellular pathogens, we have an urgent need for effective vaccines and yet there are common barriers to vaccine development. These diseases, including tuberculosis, leishmaniasis, leprosy and melioidosis, cause a huge burden of disease and disproportionately affect low and middle income countries. They are therefore often neglected due to the marginalisation of affected populations and the poor predicted commercial return on investment. Barriers to vaccine development include an incomplete understanding of protective immunity and translation from the bench into clinical vaccine trials. The current linear approach to vaccine research and development for these pathogens, which involves basic research, vaccine design, and vaccine evaluation in preclinical challenge models and clinical trials, is inefficient for these complex intracellular pathogens. We have established a Global Challenges Research Fund Network for VAccine deveLopment for complex Intracellular neglecteD pAThogEns, “VALIDATE”, where we aim to adopt a more flexible, integrated cross-pathogen approach to accelerate vaccine research and clinical development for these four pathogens, by cross-pathogen analyses, cross-discipline collaborations, and repeated integration of data from human and animal studies. This network provides a unique opportunity to bring together individuals working on four exemplar complex intracellular neglected pathogens (M.tb, Leishmania spp., B. pseudomallei and M.leprae), which share a common lifestyle as pathogens of macrophages, induce similar end-stage pathologies and alter host immune and metabolic responses. The horizontal collaborations established throughout this network, together with the provision of a protected environment for early data sharing, will exploit these biological synergies.  By interrogating mechanisms that lead from infection to disease, we will be able to develop common vaccine development strategies for these and other complex intracellular pathogens.
first_indexed 2024-12-20T20:58:01Z
format Article
id doaj.art-81e9dccdef394b8ea1d7097182dc19a6
institution Directory Open Access Journal
issn 2046-1402
language English
last_indexed 2024-12-20T20:58:01Z
publishDate 2018-04-01
publisher F1000 Research Ltd
record_format Article
series F1000Research
spelling doaj.art-81e9dccdef394b8ea1d7097182dc19a62022-12-21T19:26:47ZengF1000 Research LtdF1000Research2046-14022018-04-01710.12688/f1000research.14386.115655VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy [version 1; referees: 2 approved]Helen A. Fletcher0Mitali Chatterjee1Andrea Cooper2Tracy Hussell3Paul M. Kaye4Joann Prior5Rajko Reljic6Samantha Vermaak7Martin Vordermeier8Ann Williams9Helen McShane10The London School of Hygiene and Tropical Medicine, London, UKDepartment of Pharmacology, Institute of Postgraduate Medical Education & Research, Kolkata, IndiaDepartment of Infection, Immunity and Inflammation, University of Leicester, Leicester, UKManchester Collaborative Centre for Inflammation Research, University of Manchester, Manchester, UKCentre for Immunology and Infection, University of York, York, UKDefence Science and Technology Laboratory, Porton Down, UKInstitute for Infection and Immunity, St George's University of London, London, UKThe Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UKDepartment of Bacteriology, Animal and Plant Health Agency, Weybridge, UKNational Infection Service, Public Health England, Porton Down, UKThe Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UKFor several complex intracellular pathogens, we have an urgent need for effective vaccines and yet there are common barriers to vaccine development. These diseases, including tuberculosis, leishmaniasis, leprosy and melioidosis, cause a huge burden of disease and disproportionately affect low and middle income countries. They are therefore often neglected due to the marginalisation of affected populations and the poor predicted commercial return on investment. Barriers to vaccine development include an incomplete understanding of protective immunity and translation from the bench into clinical vaccine trials. The current linear approach to vaccine research and development for these pathogens, which involves basic research, vaccine design, and vaccine evaluation in preclinical challenge models and clinical trials, is inefficient for these complex intracellular pathogens. We have established a Global Challenges Research Fund Network for VAccine deveLopment for complex Intracellular neglecteD pAThogEns, “VALIDATE”, where we aim to adopt a more flexible, integrated cross-pathogen approach to accelerate vaccine research and clinical development for these four pathogens, by cross-pathogen analyses, cross-discipline collaborations, and repeated integration of data from human and animal studies. This network provides a unique opportunity to bring together individuals working on four exemplar complex intracellular neglected pathogens (M.tb, Leishmania spp., B. pseudomallei and M.leprae), which share a common lifestyle as pathogens of macrophages, induce similar end-stage pathologies and alter host immune and metabolic responses. The horizontal collaborations established throughout this network, together with the provision of a protected environment for early data sharing, will exploit these biological synergies.  By interrogating mechanisms that lead from infection to disease, we will be able to develop common vaccine development strategies for these and other complex intracellular pathogens.https://f1000research.com/articles/7-485/v1
spellingShingle Helen A. Fletcher
Mitali Chatterjee
Andrea Cooper
Tracy Hussell
Paul M. Kaye
Joann Prior
Rajko Reljic
Samantha Vermaak
Martin Vordermeier
Ann Williams
Helen McShane
VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy [version 1; referees: 2 approved]
F1000Research
title VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy [version 1; referees: 2 approved]
title_full VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy [version 1; referees: 2 approved]
title_fullStr VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy [version 1; referees: 2 approved]
title_full_unstemmed VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy [version 1; referees: 2 approved]
title_short VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy [version 1; referees: 2 approved]
title_sort validate exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis leishmaniasis melioidosis and leprosy version 1 referees 2 approved
url https://f1000research.com/articles/7-485/v1
work_keys_str_mv AT helenafletcher validateexploitingthesynergybetweencomplexintracellularpathogenstoexpeditevaccineresearchanddevelopmentfortuberculosisleishmaniasismelioidosisandleprosyversion1referees2approved
AT mitalichatterjee validateexploitingthesynergybetweencomplexintracellularpathogenstoexpeditevaccineresearchanddevelopmentfortuberculosisleishmaniasismelioidosisandleprosyversion1referees2approved
AT andreacooper validateexploitingthesynergybetweencomplexintracellularpathogenstoexpeditevaccineresearchanddevelopmentfortuberculosisleishmaniasismelioidosisandleprosyversion1referees2approved
AT tracyhussell validateexploitingthesynergybetweencomplexintracellularpathogenstoexpeditevaccineresearchanddevelopmentfortuberculosisleishmaniasismelioidosisandleprosyversion1referees2approved
AT paulmkaye validateexploitingthesynergybetweencomplexintracellularpathogenstoexpeditevaccineresearchanddevelopmentfortuberculosisleishmaniasismelioidosisandleprosyversion1referees2approved
AT joannprior validateexploitingthesynergybetweencomplexintracellularpathogenstoexpeditevaccineresearchanddevelopmentfortuberculosisleishmaniasismelioidosisandleprosyversion1referees2approved
AT rajkoreljic validateexploitingthesynergybetweencomplexintracellularpathogenstoexpeditevaccineresearchanddevelopmentfortuberculosisleishmaniasismelioidosisandleprosyversion1referees2approved
AT samanthavermaak validateexploitingthesynergybetweencomplexintracellularpathogenstoexpeditevaccineresearchanddevelopmentfortuberculosisleishmaniasismelioidosisandleprosyversion1referees2approved
AT martinvordermeier validateexploitingthesynergybetweencomplexintracellularpathogenstoexpeditevaccineresearchanddevelopmentfortuberculosisleishmaniasismelioidosisandleprosyversion1referees2approved
AT annwilliams validateexploitingthesynergybetweencomplexintracellularpathogenstoexpeditevaccineresearchanddevelopmentfortuberculosisleishmaniasismelioidosisandleprosyversion1referees2approved
AT helenmcshane validateexploitingthesynergybetweencomplexintracellularpathogenstoexpeditevaccineresearchanddevelopmentfortuberculosisleishmaniasismelioidosisandleprosyversion1referees2approved